Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJ1NG4)

Drug Name

Dalazatide Drug Info

Synonyms

Dalazatide [INN]; UNII-6U0259J807; 1081110-69-1; o-PHOSPHONO-L-Tyrosyl-2-(2-(2-aminoethoxy)ethoxy)acetyl(potassium channel toxin kappa-stichotoxin-shela stoichactis helianthus (caribbean sea anemone)) peptidamide; 6U0259J807

Indication

Disease Entry	ICD 11	Status	REF
Inclusion body myositis	4A41.2	Phase 1b/2a	[1]
Psoriasis vulgaris	EA90	Phase 1b/2a	[1]
Plaque psoriasis	EA90.0	Phase 1	[2]

Cross-matching ID

PubChem CID: 86278334
CAS Number: CAS 1081110-69-1
TTD Drug ID: DMJ1NG4

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Voltage-gated potassium channel Kv1.3 (KCNA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Debio-0824	DMV401D	Psoriasis vulgaris	EA90	Phase 1b/2a	[3]
UK-78282	DMKBILF	Inflammation	1A00-CA43.1	Terminated	[4]
[14C]TEA	DM6SFYH	Discovery agent	N.A.	Investigative	[5]
4-(4-phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one	DMKMH5L	Discovery agent	N.A.	Investigative	[6]
2-Methoxy-N-(3-methyl-2-phenyl-butyl)-benzamide	DM31E6J	Discovery agent	N.A.	Investigative	[7]
correolide	DMACH7K	Discovery agent	N.A.	Investigative	[8]
Correloid	DM5ISQK	Discovery agent	N.A.	Investigative	[9]
CP-339818	DMTJOWH	Discovery agent	N.A.	Investigative	[4]
5-(4-Phenylbutoxy)psoralen	DM3QFCV	Discovery agent	N.A.	Investigative	[10]
[1-Benzyl-1H-quinolin-(4E)-ylidene]-hexyl-amine	DMH3BG5	Discovery agent	N.A.	Investigative	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated potassium channel Kv1.3 (KCNA3)	TTY3UE6	KCNA3_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Durable Pharmacological Responses from the Peptide ShK-186, a Specific Kv1.3 Channel Inhibitor That Suppresses T Cell Mediators of Autoimmune Disease. J Pharmacol Exp Ther. 2012 September; 342(3): 642-653.
4	Angular methoxy-substituted furo- and pyranoquinolinones as blockers of the voltage-gated potassium channel Kv1.3. J Med Chem. 2001 Apr 12;44(8):1249-56.
5	Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol. 1994 Jun;45(6):1227-34.
6	Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol. 2005 Nov;68(5):1254-70.
7	Benzamide derivatives as blockers of Kv1.3 ion channel. Bioorg Med Chem Lett. 2003 Mar 24;13(6):1161-4.
8	Identification and biochemical characterization of a novel nortriterpene inhibitor of the human lymphocyte voltage-gated potassium channel, Kv1.3. Biochemistry. 1999 Apr 20;38(16):4922-30.
9	Potent Kv1.3 inhibitors from correolide-modification of the C18 position. Bioorg Med Chem Lett. 2005 Jan 17;15(2):447-51.
10	Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. Mol Pharmacol. 2004 Jun;65(6):1364-74.
11	Novel inhibitors of potassium ion channels on human T lymphocytes. J Med Chem. 1995 May 26;38(11):1877-83.